Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 216.39
ABAX's Cash to Debt is ranked higher than
83% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. ABAX: 216.39 )
ABAX' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: 216.39

Equity to Asset 0.85
ABAX's Equity to Asset is ranked higher than
91% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. ABAX: 0.85 )
ABAX' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.9
Current: 0.85

0.48
0.9
F-Score: 7
Z-Score: 24.24
M-Score: -2.60
WACC vs ROIC
2.36%
21.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.45
ABAX's Operating margin (%) is ranked higher than
93% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. ABAX: 15.45 )
ABAX' s 10-Year Operating margin (%) Range
Min: -930   Max: 22.65
Current: 15.45

-930
22.65
Net-margin (%) 9.72
ABAX's Net-margin (%) is ranked higher than
91% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. ABAX: 9.72 )
ABAX' s 10-Year Net-margin (%) Range
Min: -900   Max: 51.27
Current: 9.72

-900
51.27
ROE (%) 9.99
ABAX's ROE (%) is ranked higher than
85% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ABAX: 9.99 )
ABAX' s 10-Year ROE (%) Range
Min: -61.71   Max: 62.55
Current: 9.99

-61.71
62.55
ROA (%) 8.68
ABAX's ROA (%) is ranked higher than
92% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. ABAX: 8.68 )
ABAX' s 10-Year ROA (%) Range
Min: -49.56   Max: 50.99
Current: 8.68

-49.56
50.99
ROC (Joel Greenblatt) (%) 42.00
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ABAX: 42.00 )
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -154.55   Max: 57.43
Current: 42

-154.55
57.43
Revenue Growth (3Y)(%) 6.60
ABAX's Revenue Growth (3Y)(%) is ranked higher than
76% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. ABAX: 6.60 )
ABAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.6   Max: 93.9
Current: 6.6

6.6
93.9
EBITDA Growth (3Y)(%) 1.90
ABAX's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ABAX: 1.90 )
ABAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -33.7   Max: 171.4
Current: 1.9

-33.7
171.4
EPS Growth (3Y)(%) -0.50
ABAX's EPS Growth (3Y)(%) is ranked higher than
76% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. ABAX: -0.50 )
ABAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.2   Max: 159.6
Current: -0.5

-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ABAX Guru Trades in Q1 2014

PRIMECAP Management 1,979,300 sh (+244.23%)
Jim Simons Sold Out
Joel Greenblatt 20,229 sh (-21.35%)
» More
Q2 2014

ABAX Guru Trades in Q2 2014

Joel Greenblatt 26,303 sh (+30.03%)
PRIMECAP Management 1,975,700 sh (-0.18%)
» More
Q3 2014

ABAX Guru Trades in Q3 2014

Jim Simons 7,600 sh (New)
Columbia Wanger 602,000 sh (New)
PRIMECAP Management 1,973,200 sh (-0.13%)
Joel Greenblatt 16,012 sh (-39.12%)
» More
Q4 2014

ABAX Guru Trades in Q4 2014

Paul Tudor Jones 4,900 sh (New)
Joel Greenblatt 124,964 sh (+680.44%)
Jim Simons 34,000 sh (+347.37%)
Columbia Wanger 892,800 sh (+48.31%)
PRIMECAP Management 2,022,200 sh (+2.48%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Add 680.44%0.05%$47.28 - $59.81 $ 61.4614%124964
Joel Greenblatt 2014-09-30 Reduce -39.12%0.01%$41.8 - $53.11 $ 61.4631%16012
Joel Greenblatt 2014-06-30 Add 30.03%$37.95 - $44.61 $ 61.4648%26303
PRIMECAP Management 2014-03-31 Add 244.23%0.06%$36.29 - $45.01 $ 61.4655%1979300
Joel Greenblatt 2014-03-31 Reduce -21.35%0.01%$36.29 - $45.01 $ 61.4655%20229
PRIMECAP Management 2013-12-31 New Buy0.03%$32.4 - $41.25 $ 61.4667%575000
Joel Greenblatt 2013-12-31 New Buy0.02%$32.4 - $41.25 $ 61.4667%25721
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 69.80
ABAX's P/E(ttm) is ranked higher than
78% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 69.80 )
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 75.93
Current: 69.8

10.19
75.93
Forward P/E 48.78
ABAX's Forward P/E is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 48.78 )
N/A
PE(NRI) 70.40
ABAX's PE(NRI) is ranked higher than
78% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 70.40 )
ABAX' s 10-Year PE(NRI) Range
Min: 10.15   Max: 75.53
Current: 70.4

10.15
75.53
P/B 6.60
ABAX's P/B is ranked higher than
65% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. ABAX: 6.60 )
ABAX' s 10-Year P/B Range
Min: 2.19   Max: 8.03
Current: 6.6

2.19
8.03
P/S 6.80
ABAX's P/S is ranked higher than
66% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.67 vs. ABAX: 6.80 )
ABAX' s 10-Year P/S Range
Min: 2.48   Max: 9.5
Current: 6.8

2.48
9.5
PFCF 45.90
ABAX's PFCF is ranked higher than
84% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 45.90 )
ABAX' s 10-Year PFCF Range
Min: 21.92   Max: 101.52
Current: 45.9

21.92
101.52
POCF 38.94
ABAX's POCF is ranked higher than
79% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 38.94 )
ABAX' s 10-Year POCF Range
Min: 17.34   Max: 77.91
Current: 38.94

17.34
77.91
EV-to-EBIT 41.43
ABAX's EV-to-EBIT is ranked higher than
79% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 41.43 )
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6   Max: 101.7
Current: 41.43

10.6
101.7
PEG 8.59
ABAX's PEG is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 8.59 )
ABAX' s 10-Year PEG Range
Min: 0.19   Max: 13.47
Current: 8.59

0.19
13.47
Shiller P/E 79.50
ABAX's Shiller P/E is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 79.50 )
ABAX' s 10-Year Shiller P/E Range
Min: 21.13   Max: 317.57
Current: 79.5

21.13
317.57
Current Ratio 6.12
ABAX's Current Ratio is ranked higher than
89% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ABAX: 6.12 )
ABAX' s 10-Year Current Ratio Range
Min: 1.54   Max: 9.82
Current: 6.12

1.54
9.82
Quick Ratio 5.02
ABAX's Quick Ratio is ranked higher than
88% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. ABAX: 5.02 )
ABAX' s 10-Year Quick Ratio Range
Min: 1.12   Max: 8.45
Current: 5.02

1.12
8.45
Days Inventory 106.53
ABAX's Days Inventory is ranked higher than
73% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 128.32 vs. ABAX: 106.53 )
ABAX' s 10-Year Days Inventory Range
Min: 65.4   Max: 134.23
Current: 106.53

65.4
134.23
Days Sales Outstanding 56.40
ABAX's Days Sales Outstanding is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. ABAX: 56.40 )
ABAX' s 10-Year Days Sales Outstanding Range
Min: 57.8   Max: 109.5
Current: 56.4

57.8
109.5

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
ABAX's Dividend Yield is ranked lower than
83% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.23 vs. ABAX: 0.50 )
ABAX' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.53
Current: 0.5

0.21
0.53
Dividend Payout 0.34
ABAX's Dividend Payout is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 0.34 )
ABAX' s 10-Year Dividend Payout Range
Min: 0.39   Max: 0.48
Current: 0.34

0.39
0.48
Yield on cost (5-Year) 0.50
ABAX's Yield on cost (5-Year) is ranked lower than
84% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ABAX: 0.50 )
ABAX' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.53
Current: 0.5

0.21
0.53
Share Buyback Rate 0.40
ABAX's Share Buyback Rate is ranked higher than
89% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. ABAX: 0.40 )
ABAX' s 10-Year Share Buyback Rate Range
Min: 0.4   Max: -18
Current: 0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.59
ABAX's Price/Net Cash is ranked higher than
87% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 19.59 )
ABAX' s 10-Year Price/Net Cash Range
Min: 5.92   Max: 300
Current: 19.59

5.92
300
Price/Net Current Asset Value 12.51
ABAX's Price/Net Current Asset Value is ranked higher than
84% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 12.51 )
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 4.17   Max: 287.5
Current: 12.51

4.17
287.5
Price/Tangible Book 6.77
ABAX's Price/Tangible Book is ranked higher than
77% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.13 vs. ABAX: 6.77 )
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.86   Max: 36.9
Current: 6.77

2.86
36.9
Price/DCF (Projected) 3.21
ABAX's Price/DCF (Projected) is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 3.21 )
ABAX' s 10-Year Price/DCF (Projected) Range
Min: 1.7   Max: 180.9
Current: 3.21

1.7
180.9
Price/Median PS Value 1.38
ABAX's Price/Median PS Value is ranked higher than
73% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. ABAX: 1.38 )
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 8.88
Current: 1.38

0.31
8.88
Price/Peter Lynch Fair Value 6.78
ABAX's Price/Peter Lynch Fair Value is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 6.78 )
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52   Max: 11.31
Current: 6.78

0.52
11.31
Price/Graham Number 4.61
ABAX's Price/Graham Number is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 4.61 )
ABAX' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 10.96
Current: 4.61

1.42
10.96
Earnings Yield (Greenblatt) 2.40
ABAX's Earnings Yield (Greenblatt) is ranked higher than
78% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. ABAX: 2.40 )
ABAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 9.5
Current: 2.4

1
9.5
Forward Rate of Return (Yacktman) 11.84
ABAX's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.66 vs. ABAX: 11.84 )
ABAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.3   Max: 55.9
Current: 11.84

-0.3
55.9

Analyst Estimate

Mar15 Mar16 Mar17
Revenue(Mil) 215 243 273
EPS($) 0.97 1.27 1.42
EPS without NRI($) 0.97 1.27 1.42

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany,
Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market, point-of-care diagnostic instruments and consumables used in the veterinary market, and veterinary reference laboratory diagnostic and consulting services for veterinarians provided by Abaxis Veterinary Reference Laboratories (AVRL). The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Companys products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company markets and sells its products worldwide by maintaining direct sales forces and through independent distributors. It competes with Alere, Alfa Wassermann S.P.A., Johnson & Johnson (including its subsidiary, Ortho-Clinical Diagnostics, Inc.), F. Hoffmann-La Roche Ltd, Idexx Laboratories, Inc. and Heska Corporation. The Companys Piccolo products are in vitro diagnostic medical devices subj
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 
ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. Jan 13 2009 


More From Other Websites
Fresenius Medical Care (FMS) Tops Q4 Earnings, Revenues - Analyst Blog Feb 26 2015
Wright Medical Q4 Loss Narrower than Expected, Revenues Lag - Analyst Blog Feb 26 2015
Are You Considering Abaxis (ABAX) Post Solid Q3 Earnings? - Analyst Blog Feb 25 2015
Abaxis, Inc. to Present at the Raymond James 36th Annual Institutional Investors Conference Feb 25 2015
Merit Medical (MMSI) Q4 Earnings, Sales Top Estimates; Up Y/Y - Analyst Blog Feb 25 2015
Abaxis, Inc. to Present at the Raymond James 36th Annual Institutional Investors Conference Feb 25 2015
Medtronic Adds Advanced Uro-Solutions to Neuromodulation - Analyst Blog Feb 24 2015
ResMed Upped to Hold on Several Growth Initiatives - Analyst Blog Feb 24 2015
What Makes Agios Pharmaceuticals (AGIO) a Strong Sell? - Tale of the Tape Feb 24 2015
Medtronic's Artificial Pancreas Technology: Key to Diabetes Cure? - Analyst Blog Feb 23 2015
Zimmer Upbeat on Biomet Takeover, Americas Sales Disappoint - Analyst Blog Feb 23 2015
Bruker Beats Q4 Earnings by a Penny, Revenues Miss the Mark - Analyst Blog Feb 20 2015
Boston Scientific Settles $7.2B J&J Suit for $600M, Stock Up - Analyst Blog Feb 19 2015
Boston Scientific (BSX) Shows Strength: Stock Up 12.4% - Tale of the Tape Feb 19 2015
Hanger to Amend and Reissue Financial Data; Results Delayed - Analyst Blog Feb 18 2015
Medtronic Hits 52-Week High on Solid Q3, Portfolio Strength - Analyst Blog Feb 18 2015
Owens & Minor Lags Q4 Earnings Estimates, Revenues Beat - Analyst Blog Feb 18 2015
Medtronic's Spinal System Wins FDA Nod for Expanded Use - Analyst Blog Feb 17 2015
Medtronic's Euphora Balloon Catheter Family Expands in UK - Analyst Blog Feb 17 2015
Medtronic Tops Q3 Earnings, Revenues; Offers Joint Q4 View - Analyst Blog Feb 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK